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geneic blood and blood products. Apart from being a
restricted resource, transfusion of bank blood carries
the risks of serious complications: isoimmunization,
hemolytic and allergic reactions, immunosuppression,
graft-versus-host disease, and transfusion-transmitted
viral diseases such as human immunodeficiency virus/
acquired immunodeficiency syndrome, hepatitis, and
cytomegalovirus infection.1 The use of allogeneic blood
has also been shown to be a risk factor for postoperative
infection after coronary artery bypass grafting.2
Several autotransfusion techniques have evolved and
major blood conservation achievements have been
accomplished by predonation of autologous blood,3
T ransfusion of autologous blood during cardiacsurgery has routinely been practiced for more than 2
decades as part of a strategy to minimize the use of allo-
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prebypass removal of autologous blood with isovolu-
metric substitution,4 reinfusion of the volume remain-
ing in the extracorporeal circuit,5 and postoperative
autotransfusion of the shed mediastinal drainage
blood.6-10 However, the effects of autotransfusion on
biologic cascades have not been investigated in detail.
The present study reports on the effects of autotransfu-
sion on sensitive markers for activation of coagulation,
fibrinolysis, platelets, and the immunologic system,
both in the autotransfused blood at different time points
and in patients during and after autotransfusion. The
subsequent clinical consequences of the autotransfu-
sion protocol applied to a large patient population are
reviewed.
Patients and methods
Patients. From 1989 through 1997, 4956 consecutive
patients underwent myocardial revascularization with a heart-
lung machine in our department. The majority of the patients
underwent surgery on an elective basis. Only 1.7% had repeat
operations. Some types of patients were taken care of by a
neighboring university department, such as patients with
severe renal dysfunction, patients in need of a combined
carotid and coronary operation, and those facing true emer-
gencies such as failed angioplasties. Otherwise, a typical pop-
ulation of patients undergoing coronary artery bypass was
treated (Table I). All patients, without any exclusions, under-
went a consistent blood conservation protocol, previously
described in detail.11 The main steps included (1) removal of
autologous blood before cardiopulmonary bypass (CPB) for
retransfusion after CPB (in patients with normal preoperative
red cell volume), (2) intraoperative retransfusion of oxygena-
tor and tubing contents, and (3) postoperative autotransfusion
of shed mediastinal blood up to 18 hours after the operation.
In a subset of 40 randomly selected male patients elective-
ly admitted for coronary artery bypass grafting (study group),
a series of laboratory tests was performed. Exclusion criteria
included anticoagulation, antiplatelet therapy administered
less than 7 days before the operation, and unstable angina.
Also patients with an estimated hematocrit value less than
22% during CPB were excluded because of removal of sub-
stantial blood samples. When eligible, the study patients were
selected during a 5-month period, being the first patients on
the operation program. This was done because of logistic rea-
sons, to be able to sample and handle all the blood specimens.
The study protocol for these patients was approved by the
regional ethics committee and informed consent was obtained
from all patients.
The total patient population except for the 40 patients in the
study group are referred to as the main group.
Operation
All patients. During the entire period under investigation
(1989-1997), the treatment strategies have remained
unchanged in all major aspects. More than two thirds of the
patients were operated on by one of two surgeons. The anes-
thesia protocol was designed to permit early postoperative
extubation and included mainly a combination of diazepam
(0-0.2 mg/kg), midazolam hydrochloride (0-0.2 mg/kg), fen-
tanyl (6-8 mg/kg), and pancuronium bromide supplemented
with isoflurane and nitrous oxide.
Autologous blood was withdrawn before CPB from all
patients in whom the estimated hemodilution on CPB was
expected to exceed a hematocrit value of 22%. After
heparinization and insertion of the cannulas, blood was
drained by gravity into blood bags and stored at room tem-
perature for retransfusion at the conclusion of CPB. To pre-
vent hemodynamic instability, the blood volume removed
was replaced with the priming solution through the aortic
cannula.
If available, at least one internal thoracic artery was graft-
ed, supplemented with saphenous vein grafts. Surgical hemo-
stasis was completed before reversal of the anticoagulation
with protamine sulphate at a ratio of 1.3 mg of protamine to
1 mg of heparin. The residual CPB circuit blood from the
oxygenator and the tubing set was drained into blood bags
and retransfused in the operating room or in the intensive care
unit. For postoperative autotransfusion of mediastinal shed
blood, the mediastinal and pleural tubes were connected to
the hard-shell cardiotomy reservoir used during extracorpore-
al circulation, and the blood was retransfused hourly through
a 20- m m infusion filter. Normovolemic anemia was accepted
to a hematocrit value of 25% after the operation; a level
below this was considered an indication for allogeneic red
blood cell transfusion. No antifibrinolytic drug or other
agents to reduce bleeding were routinely given.
Study group. Blood samples were drawn with a syringe
from the central venous cannula, discarding the first 10 mL,
at the following intervals: (1) after induction of anesthesia,
(2) immediately after termination of CPB but before admin-
istration of protamine, (3) 1 hour after the operation, (4) 2
hours after the operation, (5) 4 hours after the operation, and
Table I. Demographic and operative data of the main
group (n = 4916) and the study group (n = 40)
Main group Study group P value
Age (y) 63 (56-69) 64 (55-69) .2
Female proportion (%) 16.4 – —
Patients with previous MI 55.1 52.5 .9
(%)
Ejection fraction (%) 70 (60-77) 72 (64-80) .2
Left main stenosis (%) 19.3 7.5 .1
Diabetes (%) 8.6 12.5 .2
At least 1 ITA graft (%) 99.1 100 .2
No. of distal anastomoses 4 (3-5) 5 (3.5-5) .03
Ischemic time (min) 32 (25-39) 31 (25-36) .4
ECC (min) 57 (46-67) 52 (44-60) .02
There were no statistically significant intergroup differences, except for exclu-
sion of women in the study group and small differences concerning number of
distal anastomoses and time of extracorporeal circulation. Median values are
given, with quartiles in parentheses. MI, Myocardial infarction; ITA, internal
thoracic artery; ECC, extracorporeal circulation.
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(6) 18 hours after the operation. As the mediastinal drainage
volume was retransfused every hour, the postoperative blood
sample time points were chosen to detect possible direct
effects of the autotransfusion.
In vitro blood was withdrawn with a syringe via a 3-way
stopcock, which was connected to the blood bags and the car-
diotomy reservoir. The samples were harvested at the follow-
ing intervals: (1) from the pre-CPB pooled autologous blood
immediately before retransfusion, after termination of CPB,
(2) from the residual CPB-circuit blood directly before
retransfusion, and (3-5) from the mediastinal shed blood
immediately before retransfusion 1, 2, and 4 hours after the
operation.
Blood specimens from the patients and the in vitro blood
were injected into (1) EDTA K3 Vacutainer tubes (15%, 0.34
mol/L) (Becton Dickinson & Co, Rutherford, NJ) for com-
plement/cytokine analysis and platelet count, (2) sodium cit-
rate tubes (1/10 volume of 0.129 mol/L) (Becton Dickinson)
for coagulation, fibrinolysis, and heparin analysis, and (3)
DiatubeH tubes (Diagnostica Stago, Asnieres-sur-Seine,
France) for b -thromboglobulin (b -TG) determination. All
specimens, except those for whole-blood platelet count, were
immediately cooled with ice slush and centrifuged as soon as
possible: EDTA Vacutainer tubes: 1500g, 10 minutes, 4°C;
sodium-citrate Vacutainer tubes: 1500g, 10 minutes, room
temperature; heparin 2000-4000g, 20 minutes, 4°C;
DiatubeH tubes: 2500g, 30 minutes, 4°C. Plasma samples
were stored at –70°C until assayed.
Analyses. The thrombin-antithrombin (TAT) complex, the
prothrombin fragment 1.2 (PF1.2), and the plasmin/ a 2-
antiplasmin (PAP) complex were all assayed with the use of
an enzyme-linked immunoassay according to the instructions
given by the manufacturer (Enzygnost TAT/F1+2/PAP micro,
Behringwerke AG, Diagnostica, Marburg, Germany).
Detection of thrombin in mediastinal shed blood was deter-
mined as follows: Citrated supernatant from centrifuged shed
blood (100 m L) was added to purified human fibrinogen (200
m L, 2 mg/mL of Tris-HCl buffer, pH 7.4). The mixture was
observed at 37°C for 20 minutes for potential clot formation.
The platelet activation marker b -TG was measured with an
enzyme-linked immunosorbent assay as described by the
manufacturer (Asserachrom b -TG, Diagnostica Stago).
Fibrinogen concentration was determined according to the
method of Clauss.12
NycoCard D-dimer immunoassay (Nycomed Pharma,
Oslo, Norway) was used for determination of D-dimer. 
Total plasma heparin was determined by a chromogenic
anti-FXa assay (Coatest Heparin, Chromogenix AB,
Mölndal, Sweden).
For measurement of the heparin cofactor activity of
antithrombin, a chromogenic assay was used in accordance
with the manufacturer´s instructions (Coamatic Anti-
thrombin, Chromogenix AB).
The concentration of plasma free hemoglobin was mea-
sured by a colorimetric method according to Hunter, Grove-
Rasmussen, and Soutter13 modified by us for use on Titertek
Twinreader PLUS device (Labsystems Oy, Helsinki, Finland).
Platelet count was determined with an automatic cell
counter (Cobas Minos ST; Roche, Basel, Switzerland).
Protein C was determined in the supernatant from cen-
trifuged shed blood samples with a chromogenic assay
(Coamatic Protein C, Chromogenix AB). Appropriate blanks
were made from each supernatant, subtracting blank values
before calculations of results.
The concentration of the fluid-phase terminal complement
complex (TCC) was measured according to the method of
Mollnes and associates,14 which is based on a double-anti-
body enzyme-linked immunosorbent assay with monoclonal
antibodies specific for a neoantigen of polymeric C9.
The C3 activation products (C3bc) were quantified in a
double-antibody enzyme-linked immunosorbent assay
described by Garred, Mollnes, and Lea,15 using monoclonal
antibodies specific for the C3 neoepitope expressed on C3b,
iC3b, and C3c as capture antibody.
An immunoenzymometric assay (EASIA; enzyme ampli-
fied sensitivity immunoassay) was used for the quantitative
measurement of the cytokine tumor necrosis factor a and the
cytokine interleukin-6 in accordance with the manufacturer´s
instructions (Medgenix, Diagnostics, Fleurus, Belgium).
Statistics. The data are presented as median with quartiles.
Longitudinal changes between 2 time points only were ana-
lyzed using the paired Student t test. Linear regression analy-
sis was used to test the statistical correlation between the
measured laboratory data from the patients 4 hours after the
operation (after having received the major part of the retrans-
fused blood) and the values in the mediastinal shed blood 2
hours after the operation. All data during CPB are given
uncorrected for hemodilution. All data were recorded
prospectively and stored in a database.
Results
Study group. Demographic and operative data were
similar to the main group population except for exclu-
sion of female gender and a slight difference in CPB
time (Table I). All patients had autologous blood with-
drawn before CPB for retransfusion after CPB (Table
II). The amount of autotransfusion of mediastinal shed
blood was smaller in the study group than in the main
group (P = .01), mainly due to blood sampling from the
reservoir. The clinical course was uneventful in all
patients (Table III). There were no incidents of postop-
erative myocardial infarction or stroke, and all patients
survived. No allogeneic blood products were given.
Antifibrinolytic drugs were not administered to any
patient.
Autologous blood withdrawal. The heparinized
autologous blood withdrawn before CPB was stored at
room temperature during the time of extracorporeal cir-
culation, that is, for about 1 hour. Some activation of
platelets was assessed by a statistically significant ele-
vation of the levels of b -TG to a median of 83 IU/mL
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(51-120 IU/mL) compared with the preoperative level
of 31 IU/mL (24-37 IU/mL) (P < .01). Otherwise there
was no detectable activation of coagulation, fibrinoly-
sis, or immunologic systems.
CPB circuit content. The analyses performed on the
blood samples taken from the CPB circuit content
immediately before retransfusion are listed in Table IV.
Compared with preoperative values, coagulation and
fibrinolysis studies revealed statistically significant ele-
vation of TAT complex, PF1.2, b -TG, and PAP complex,
whereas the concentrations of antithrombin and fi-
brinogen were significantly decreased. Also the mark-
ers for complement activation and cytokine release
were found to be significantly higher than the preoper-
ative levels. Measurable levels of plasma free hemoglo-
bin and heparin were found.
Mediastinal shed blood and circulating plasma.
Extremely high levels of markers for thrombin and fi-
brin generation, as well as platelet activation, were seen
in the mediastinal shed blood (Table V). Interestingly,
no clotting was observed after 20 minutes’ incubation
of shed blood with purified human fibrinogen, exclud-
ing significant amounts of thrombin to be present. The
mediastinal shed blood contained very small amounts
of fibrinogen in all postoperative samples. In the circu-
lating plasma, a statistically significant elevation of
these markers was seen during and after the operation
(Table VI).
A pattern similar to that seen for the coagulation sys-
tem was demonstrated for fibrinolytic activity, as
assessed by PAP complex in the mediastinal shed
blood, as well as in circulating plasma (Tables V and
VI). Fibrinolytic activity in the mediastinal shed blood
was further evidenced by high and increasing levels of
fragment D-dimer during the postoperative time.
Elevated concentrations of plasma free hemoglobin
were seen in the mediastinal shed blood and increased
slightly during the 4 postoperative hours (Table V). No
significant changes in plasma free hemoglobin in cir-
culating plasma occurred during and after the opera-
Table II. Blood conservation data in the main group
(n = 4916) and the study group (n = 40)
Main group Study group P value
Autologous blood  880 (600-1050) 1000 (800-1060) .07
removal before CPB 
(mL) (n = 4232)
Mediastinal drainage 650 (525-820) 560 (500-720) .1
18 hours postop (mL)
Autotransfusion of 630 (505-800) 468 (413-645) .01
shed blood (mL)
Resternotomy for 149 (2.9%) 0
bleeding (patients)
RBC transfusion 113 (2.3) 0
(+/–plasma) (patients)
Plasma or platelet 56 (1.2%) 0
transfusion (patients)
Preop Hgb 146 (137-153) 146 (143-153) .5
concentration (gm/L)
Hgb concentration at 120 (110-130) 117 (113-128) .9
discharge (gm/L)
Values are given as median values with quartiles in parentheses. CPB,
Cardiopulmonary bypass; RBC, red blood cell; Hgb, hemoglobin.
Table III. Postoperative complications in the main
group (n = 4916) and the study group (n = 40) 
Main group Study group P value
Ventilatory support (h) 1.5 (1.0-2.0) 1.7 (1.1-2.2) .1
Reintubated after 55 (1.1%) 0 .5
extubation (patients)
Periop MI (patients) 128 (2.6%) 0 .3
Postop renal failure 3 (0.1%) 0 .9
(dialysis) (patients)
Mediastinitis 25 (0.6%) 0 .7
Permanent cerebral 44 (0.9%) 0 .6
dysfunction (patients)
Transient neurologic 28 (0.6%) 0 .6
events (patients)
Physical rehabilitation 4558 (92%) 39 (97.5%) 1.0
within 5 days (patients)
Hospital mortality 22 (0.44%) 0 .7
(patients)
Values are given as median values with quartiles in parentheses. MI,
Myocardial infarction.
Table IV. Characteristics of the CPB circuit blood
compared with preoperative levels in the patients
(n = 40) 
Preop CPB circuit P value
Heparin (IU/mL) 0.1 (0.1-0.1) 4 (4-5) <.001
TAT (m g/L) 3.5 (2.6-5.7) 89 (49-100) <.001
PF1.2 (nmol/L) 1.0 (0.8-1.5) 4.3 (3.0-5.2) <.001
b -TG (IU/mL) 31 (24-37) 270 (200-400) <.001
PAP (m g/L) 410 (290-470) 780 (450-1400) <.001
Antithrombin (%) 100 (92-100) 62 (54-71) <.001
Fibrinogen (g/L) 3.0 (2.7-4.0) 1.8 (1.6-2.1) <.001
pHgb (g/dL) 0 (0-0.01) 0.05 (0.04-0.07) .9
IL-6 (pg/mL) 6.2 (4.5-8.6) 29 (18-41) <.001
TNF-a (pg/mL) 14 (12-18) 19 (14-22) <.001
TCC (AU/mL) 4.0 (3.0-5.0) 77 (49-130) <.001
C3bc (AU/mL) 9.0 (7.5-11) 80 (61-120) <.001
Values are given as median values with quartiles in parentheses. Heparin,
Total plasma heparin; TAT, thrombin-antithrombin complex; PF1.2, prothrom-
bin fragment 1.2; b -TG, b -thromboglobulin; PAP, plasmin- a 2-antiplasmin
complex; pHgb, plasma free hemoglobin; IL-6, interleukin-6; TNF- a , tumor
necrosis factor a ; TCC, terminal complement complex; C3bc, C3 activation
products.
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tion, and only small amounts of plasma free hemoglo-
bin were detected (Table VI).
In the patients, total plasma heparin concentration
reached a peak at the end of CPB (Table VI).
Postoperative measurements indicated adequate rever-
sal of anticoagulation with protamine.
The content of protein C in mediastinal shed blood
varied between 37% and 94%. Since the protein C
assay would include both nonactivated as well as acti-
vated protein C, the assay was also performed without
protein C activator to measure the amount of pre-acti-
vated protein C. Thus pre-activated protein C ranged
from 0% to 30.5%.
Concerning the immunologic system, the comple-
ment activation products and cytokines were highly
elevated in the shed blood compared with the preoper-
Table V. Characteristics of the mediastinal shed blood in the study group (n = 40) during the 1st, 2nd, and 4th
postoperative hours 
1st hour 2nd hour 4th hour
Heparin (IU/mL) 0.1 (0.1-0.2) 0.1 (0.1-0.1) 0.1 (0.1-0.1)
TAT (m g/L) 21,000 (14,000-25,000) 23,000 (18,000-28,000) 25,000 (20,000-30,000)
PF1.2 (nmol/L) 430 (280-540) 430 (310-560) 340 (230-550)
b -TG (IU/mL) 5,100 (3,300-7,300) 5,200 (4,000-6,800) 5,500 (3,800-6,700)
PAP (m g/L) 5,200 (3,400-7,600) 13,000 (9,400-20,000) 17,000 (11,000-24,000)
AT (%) 45 (38-52) 43 (33-51) 39 (30-48)
Fibrinogen (g/L) 0.040 (0.040-0.040) 0.040 (0.040-0.040) 0.040 (0.040-0.040)
pHgb (g/dL) 0.4 (0.3-0.5) 0.4 (0.3-0.5) 0.6 (0.4-0.8)
FDP (mg/L) 60 (35-90) 190 (140-290) 380 (190-570)
C3bc (AU/mL) 110 (86-140) 110 (95-140) 120 (97-152)
TCC (AU/mL) 63 (51-84) 110 (86-140) 150 (120-230)
TNF-a (pg/mL) 44 (36-64) 43 (32-60) 40 (29-50)
IL-6 (pg/mL) 2,700 (1,400-3,900) 17,000 (12,000-24,000) 81,000 (52,000-90,000)
Values are given as median values with quartiles in parentheses. Heparin, Total plasma heparin; TAT, thrombin-antithrombin complex; PF1.2, prothrombin fragment
1.2; b -TG, b -thromboglobulin; PAP, plasmin- a 2-antiplasmin complex; AT, antithrombin; pHgb, plasma free hemoglobin; FDP, D-dimer; C3bc, C3 activation prod-
ucts; TCC, terminal complement complex; TNF- a , tumor necrosis factor a ; IL-6, interleukin-6.
Table VI. Coagulation and fibrinolysis parameters in the circulating plasma in the study group (n = 40)
Time points
Analyses Preop End CPB 1 h postop 2 h postop 4 h postop 18 h postop
Heparin (IU/mL) 0.1 (0.1-0.1) 5 (4-6) 0.1 (0.1-0.2) 0.1 (0.1-0.2) 0.1 (0.1-0.2) 0.1 (0.1-0.1)
TAT (µg/L) 3.5 (2.6-5.7) 31 (21-41) 26 (21-36) 45 (30-120) 110 (57-180) 24 (16-38)
PF1.2 (nmol/L) 1.0 (0.8-1.5) 2.5 (1.7-3.0) 3.2 (2.3-4.5) 4.4 (3.4-6.8) 6.8 (4.9-9.9) 2.9 (2.0-4.7)
b -TG (IU/mL) 31 (24-37) 150 (120-210) 130 (77-180) 100 (75-150) 89 (61-110) 33 (26-43)
Platelet count (· 103/mm3) 182 (160-240) 160 (130-210) 180 (150-220) 190 (170-230) 190 (160-240) 180 (160-220)
PAP (m g/L) 410 (290-470) 680 (380-1200) 760 (600-960) 850 (650-1100) 1200 (890-1500) 480 (390-610)
AT (%) 100 (92-100) 65 (59-73) 91 (82-100) 98 (88-100) 100 (89-100) 100 (96-100)
Fibrinogen (g/L) 3.0 (2.7-4.0) 1.9 (1.6-2.0) 2.6 (2.2-3.2) 2.7 (2.4-3.3) 2.9 (2.5-3.4) 4.5 (4.1-5.1)
pHgb (g/dL) 0 (0-0.01) 0.03 (0.02-0.04) 0.03 (0.02-0.04) 0.03 (0.02-0.04) 0.02 (0.01-0.04) 0 (0-0.01)
Values are given as median values with quartiles in parentheses. Heparin, Total plasma heparin; TAT, thrombin-antithrombin complex; PF1.2, prothrombin fragment
1.2; b -TG, b -thromboglobulin; PAP, plasmin- a 2-antiplasmin complex; AT, antithrombin; pHgb, plasma free hemoglobin.
Table VII. Inflammatory markers in the circulating plasma in the study group (n = 40)
Time points
Analyses Preop End CPB 1 h postop 2 h postop 4 h postop 18 h postop
C3bc (AU/mL) 9.0 (7.5-11) 52 (39-69) 79 (58-110) 49 (30-78) 21 (16-33) 8.0 (6.0-10)
TCC (AU/mL) 4.0 (3.0-5.0) 38 (28-52) 21 (13-29) 12 (8.5-16) 7.0 (6.0-10) 4.0 (4.0-6.0)
TNF-a (pg/mL) 14 (12-18) 15 (12-18) 24 (18-30) 23 (17-28) 19 (13-21) 13 (9.6-17)
IL-6 (pg/mL) 6.2 (4.5-8.6) 23 (16-29) 140 (120-180) 240 (160-360) 240 (160-360) 300 (220-390)
Values are given as median values with quartiles in parentheses. C3bc, C3 activation products; TCC, terminal complement complex; TNF- a , tumor necrosis factor
a ; IL-6, interleukin-6.
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ative values in the patients (Tables V and VII). In par-
ticularly, the interleukin-6 increased continuously in
the first postoperative hours, both in the shed blood and
in the circulating plasma. The cytokine tumor necrosis
factor a concentration in the mediastinal shed blood
was approximately 3 times higher than the preoperative
values in the patients.
Linear regression analysis revealed a statistical corre-
lation between most of the patient plasma values mea-
sured 4 hours after the operation and the values in the
mediastinal shed blood 2 hours after the operation
(Table VIII).
Main group. The demographic and operative data
are shown in Table I. The most relevant blood conser-
vation parameters are displayed in Table II.
Postoperative bleeding was moderate, and almost all
mediastinal shed blood was autotransfused. In an
extreme case as much as 5375 mL was returned to the
patient without any harmful effects. Transfusion of
allogeneic blood or blood products was seldom neces-
sary (3.5%), needed mainly in elderly women and
patients reoperated on for bleeding. The hemoglobin
concentrations were satisfactory in both groups at dis-
charge from the hospital (Table II). Complications were
few (Table III), and most of the patients were able to
walk stairs or outside the hospital within 5 days after
the operation. The overall hospital mortality was
0.44%.
Discussion
Awareness of the risks of allogeneic transfusions is
the main motivation for blood conservation after car-
diac operations. A wide variety of blood conservation
techniques has been developed and, apart from meticu-
lous surgical techniques, the 2 principal approaches
have been autotransfusion and hemostatic drug therapy.
The present report deals with the influence of a simple
perioperative autotransfusion protocol on the coagula-
tion system, platelets, fibrinolysis, and the inflammato-
ry response. The overall subsequent clinical conse-
quences of the autotransfusion procedures were
evaluated in a consecutive series of 4916 patients.
Intraoperative withdrawal of whole blood for retrans-
fusion after CPB provides the immediate postoperative
availability of fresh blood containing clotting factors,
intact platelets, leukocytes, and red blood cells.4,16 This
procedure has been shown to reduce postoperative
bleeding and consequently allogeneic blood require-
ment and enhances hemodilution during CPB, which in
turn reduces intraoperative hemoglobin loss.17 To our
knowledge, no data so far have been available concern-
ing potential activation of fresh blood stored at room
temperature in the present setting. Except for some ele-
vation of platelet b -TG, our study demonstrated
absence of any activation of the biologic systems under
investigation. These findings confirm the high quality
of this pooled autologous blood.
The return of the CPB circuit blood immediately
after CPB has in some studies proved to reduce the
need for allogeneic transfusions,18 whereas others
claim that this method contributes to postoperative
bleeding problems and impairment of hemostasis.19
Although the residual volume in the extracorporeal cir-
cuit is assumed to reflect the state of the patient’s blood
at the end of CPB, little information regarding the acti-
vation of this specific blood component has been pub-
lished. Our study revealed some activation of coagula-
tion, platelets, and fibrinolysis, as evidenced by
moderately elevated levels of TAT complex, PF1.2, b -
TG, and PAP complex when compared with preopera-
tive values. Also, markers for inflammatory response
were elevated. Except for the beneficial effects of
autologous blood salvage, the true clinical effects of
returning the residual circuit contents to the patients
remain unclear. Certainly, the effects may be masked
by the subsequent autotransfusion of the extensively
more activated mediastinal shed blood.
Autotransfusion of postoperative mediastinal shed
blood has been widely used for blood conservation dur-
ing the past 2 decades. The safety and the blood salvage
effects have been well documented,7-11 and return of
the shed blood has been proved by the lack of septic,
pulmonary, or hepatic complications.20 However, some
authors have questioned the quality of the blood col-
lected, and there have been indications of impaired
hemostasis,21,22 and even disseminated intravascular
coagulation in dogs,23 after autotransfusion of medi-
astinal shed blood.
Complete coagulation could be demonstrated as evi-
denced by the total absence of fibrinogen in the untreat-
ed, mediastinal shed blood. However, the present study
could also demonstrate extremely high levels of mark-
ers for activation of both the coagulation and fibri-
nolytic systems, as well as for the inflammatory
response. A statistically significant correlation was
found between the elevations of these markers in the
mediastinal shed blood and systemic plasma during the
first postoperative hours. These indications of an
extreme thrombin formation, with a reduced level of
antithrombin and virtually no heparin present in the
mediastinal shed blood, might suggest an insufficient
clotting inhibition and, consequently, infusion of active
thrombin during the autotransfusion procedure. The
test for thrombin activity, however, was negative.
As no thrombin was found in the mediastinal shed
blood, the measured pre-activated protein C ranging
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from 0% to 30.5% might have been activated in the cir-
culation. Other studies also indicate this mechanism.7,8
The presence of protein C ranging between 37% and
94% in shed blood during the postoperative time might
add to the safety of the autotransfusion of mediastinal
shed blood. The presence of protein C in shed blood has
also been reported by others, even in higher concentra-
tions than in bank blood.8 The return of both TAT com-
plex and PF1.2 to nearly preoperative levels 18 hours
after the operation, despite continuous autotransfusion
during this time, supports the safety of this practice.
A strong platelet activation was also evident, as high-
ly elevated levels of b -TG were seen in the shed blood
after the operation, about 35 times the systemic con-
centration at the end of CPB. This correlated well with
the elevations seen in patient plasma during the first
postoperative hours. No clinical hemostatic conse-
quences could be demonstrated. Despite the very high
levels of fibrinolytic parameters in the shed blood, like
PAP complex and D-dimer, disturbing bleeding prob-
lems were rare. This is reflected in an acceptable
amount of postoperative drainage (median 650 mL) in
the total patient population.
In accordance with other investigators,6,8 the medi-
astinal shed blood in this study contained increased
levels of plasma free hemoglobin. This is probably
mainly due to mechanical damage of red blood cells
during CPB,20 but may also be partly due to activation
of the complement system during and after the opera-
tion.6 On the other hand, others have demonstrated that
exposure of shed blood to the cardiotomy reservoir
does not exacerbate blood cell damage, as survival of
red blood cells from mediastinal shed blood after auto-
transfusion is comparable with the survival of red
blood cells in the patients’ circulating blood.24 In the
present study, no statistically significant correlation
could be registered between the plasma free hemoglo-
bin concentration in the patients and in the mediastinal
shed blood. It should further be borne in mind that bank
blood also contains high levels of free hemoglobin after
normal storage.25
As for the immunologic system, both the residual
content of the CPB circuit and particularly the medi-
astinal shed blood contained large amounts of
cytokines and complement activation products. The
consequences of retransfusion of these markers remain
unclear. Although release of cytokines and activation of
the complement cascade are known to take part in the
inflammatory response during and after CPB opera-
tions,26 there were no clinical signs of unexpected
organ failure. In the total patient population, the medi-
an time on postoperative ventilatory support was 1.5
hours, and incidents of postoperative renal failure were
rare. Tumor necrosis factor a has further been shown to
impair wound healing over time by directly suppress-
ing collagen synthesis and collagen gene expression.27
There were no clinical correlating signs or symptoms,
which is partly reflected in a low infection rate. A nor-
malization of the plasma concentrations of the inflam-
matory markers occurred on the first postoperative day,
although autotransfusion was consistently performed
during the entire period. It might be suggested that reg-
ulatory mechanisms may effectively neutralize the
infusion of these components, at least in patients with
normal renal function.
Despite the extensive alterations in the autotrans-
fused blood regarding thrombin formation, platelet
activity, fibrinolytic activity, and activation of the
immunologic system, the clinical effects of autotrans-
fusion should be evaluated in larger patient series. On
the basis of rather limited numbers of patients, some
authors have questioned the benefit of autotransfusion,
suggesting either increased bleeding tendency21 or
lacking reduction in postoperative blood loss or
requirements for allogeneic transfusions.28 However,
the present experience with nearly 5000 consecutive
patients undergoing coronary bypass with a consistent
autotransfusion protocol could demonstrate a high
level of safety without any significant transfusion-relat-
ed side-effects, as well as an allogeneic transfusion rate
of less than 4%.
In conclusion, the present investigation indicates that
Table VIII. Linear regression analysis between the
measured laboratory data from the study group 
(n = 40) 4 hours postoperatively and the values in
the mediastinal shed blood 2 hours postoperatively
(n = 40)
Analysis Correlation coefficient (r) P value
TAT 0.48 <.01
PF1.2 0.42 <.01
b -TG 0.58 <.001
PAP 0.32 <.05
AT 0.68 <.001
pHgb –0.11 >.2
Heparin 0.29 <.1
C3bc 0.66 <.001
TCC 0.23 <.2
TNF-a 0.43 <.01
IL-6 0.15 >.2
TAT, Thrombin-antithrombin complex; PF1.2, prothrombin fragment 1.2; b -
TG, b -thromboglobulin; PAP, plasmin- a 2-antiplasmin complex; AT,
antithrombin; pHgb, plasma free hemoglobin; heparin, total plasma heparin;
C3bc, C3 activation products; TCC, terminal complement complex; TNF- a ,
tumor necrosis factor a ; IL-6, interleukin-6.
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the autologous blood removed before CPB was close to
non-activation, whereas the content of the CPB circuit
was moderately activated and the mediastinal shed
blood excessively activated regarding coagulation,
platelets, fibrinolysis, and immunologic response.
However, retransfusion of all these available autologous
blood resources to a large patient population did not
carry any clinical disadvantages or harmful effects. The
need for allogeneic blood products was minimal, with
preservation of an adequate hemoglobin concentration.
Thus the present data clearly indicate a major disparity
between laboratory tests and clinical performance.
We thank Michel Abdelnoor, PhD, for skillful statistical
assistance, and Tom Eirik Mollnes, MD, PhD, for performing
the complement analyses.
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